Tissuse GmbH

Tissuse GmbH is an SME in Berlin, Germany that has taken part in 7 EU-funded projects since 2016, receiving €3.9M in EU funding.

EU funding received€3.9M
EU projects7
As coordinator0
Running now3
First EU project2016
Latest project2023
CountryGermany
EU registration (PIC)986179504
On this page · 5 sections→

Where the EU money came from

Funding by EU programme. Amounts are Tissuse GmbH's own share of each project, not the project's full budget.

  • Horizon 2020€2.8M · 5 projects
  • Horizon Europe€1.1M · 2 projects

Projects

7 EU-funded projects, newest first. Each links to the official record.

  • TOP-GUTPartner

    Training for Organoids modelling Physiology and Pathology in the human gastrointestinal tract

    Horizon Europe · 2023–2027 · Project on CORDIS ↗

    €261ktheir share
  • geneTIGAPartner

    Gene-edited T cells combating IgA Nephropathy. A blueprint approach for safe & efficient genome editing of T cells to sustainably combat several immune diseases and cancers related to B-cell pathology

    Horizon Europe · 2022–2026 · Project on CORDIS ↗

    €873ktheir share
  • RISK-HUNT3RPartner

    RISK assessment of chemicals integrating HUman centric Next generation Testing strategies promoting the 3Rs

    Horizon 2020 · 2021–2026 · Project on CORDIS ↗

    €650ktheir share
  • BIRDIEPartner

    Bioprinting on-chip microphysiological models of humanized kidney tubulointerstitium

    Horizon 2020 · 2021–2025 · Project on CORDIS ↗

    €500ktheir share
  • RESTOREPartner

    RESTORE Health by Advanced Therapies (Advanced Therapy Medicinal Products and Biologized Medical Devices) – ALL for Advanced Therapies – with Passion – For Patients

    Horizon 2020 · 2019–2020 · Project on CORDIS ↗

    €15ktheir share
  • RESHAPEPartner

    Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

    Horizon 2020 · 2019–2024 · Project on CORDIS ↗

    €944ktheir share
  • EU-ToxRiskPartner

    An Integrated European ‘Flagship’ Program Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st Century

    Horizon 2020 · 2016–2021 · Project on CORDIS ↗

    €695ktheir share

Works most with

Organisations that shared the most EU projects with this one. A good starting list for consortium partners.

Fields it works in

Research fields recorded on its Horizon projects.

  • RNA
  • diabetes
  • drug discovery
  • gene therapy
  • genomes
  • immunotherapy
  • inflammatory diseases
  • microscopy
  • mortality
  • nephrology
  • oncology
  • organ on a chip
  • pathology
  • personalized medicine

Is this your organisation?

Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.

Claim this profile →

Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships.

Europe’s tech funding.
One place.

The weekly briefing

Funding calls, VC news and key deadlines — a weekly briefing for European founders.

Free · unsubscribe anytime